Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|7-1048|1|74-83

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.7-1048, Iss.1, 2015-10, pp. : 74-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 74-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin

By  

Acta Haematologica, Vol. 137, Iss. 3, 2017-03 ,pp. : 123-131

Karger

Access to resources Recommend Favorite

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma

By  

Oncology, Vol. 87, Iss. 4, 2014-07 ,pp. : 224-231

Karger

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite